Titan Pharmaceuticals Inc. (TTNP)’s Financial Results Comparing With Eyenovia Inc. (NASDAQ:EYEN)

Titan Pharmaceuticals Inc. (NASDAQ:TTNP) and Eyenovia Inc. (NASDAQ:EYEN), both competing one another are Biotechnology companies. We will compare their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Titan Pharmaceuticals Inc. N/A 0.00 51.92M -1.85 0.00
Eyenovia Inc. 3 0.00 9.87M -1.86 0.00

Table 1 highlights Titan Pharmaceuticals Inc. and Eyenovia Inc.’s gross revenue, earnings per share and valuation.


Table 2 represents Titan Pharmaceuticals Inc. (NASDAQ:TTNP) and Eyenovia Inc. (NASDAQ:EYEN)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Titan Pharmaceuticals Inc. 29,550,369,948.78% -319.2% -106.8%
Eyenovia Inc. 313,761,642.88% -108.8% -97.2%


The current Quick Ratio of Titan Pharmaceuticals Inc. is 1.9 while its Current Ratio is 2.1. Meanwhile, Eyenovia Inc. has a Current Ratio of 5.9 while its Quick Ratio is 5.9. Eyenovia Inc. is better positioned to pay off its short-term and long-term debts than Titan Pharmaceuticals Inc.

Analyst Ratings

The Ratings and Recommendations for Titan Pharmaceuticals Inc. and Eyenovia Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Titan Pharmaceuticals Inc. 0 0 1 3.00
Eyenovia Inc. 0 0 0 0.00

The upside potential is 455.56% for Titan Pharmaceuticals Inc. with average price target of $1.

Insider and Institutional Ownership

Roughly 5.1% of Titan Pharmaceuticals Inc. shares are held by institutional investors while 8.1% of Eyenovia Inc. are owned by institutional investors. Insiders held 4.32% of Titan Pharmaceuticals Inc. shares. Competitively, insiders own roughly 4.6% of Eyenovia Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Titan Pharmaceuticals Inc. -3.48% -12.94% -32.32% -7.5% -79.44% -17.04%
Eyenovia Inc. -0.93% -25.81% -46.02% -3.04% -46.83% 11.93%

For the past year Titan Pharmaceuticals Inc. had bearish trend while Eyenovia Inc. had bullish trend.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.

Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.